Vaccine Adjuvants: Putting Innate Immunity to Work
By R. Coffman, A. Sher, R. Seder. Immunity, 2010
1,853 citations recorded by the source corpus.
Adjuvants enhance immunity to vaccines and experimental antigens by a variety of mechanisms. In the past decade, many receptors and signaling pathways in the innate immune system have been defined and these innate responses strongly influence the adaptive immune response. The focus of this review is to delineate the innate mechanisms by which adjuvants mediate their effects. We highlight how adjuvants can be used to influence the magnitude and alter the quality of the adaptive response in order to provide maximum protection against specific pathogens. Despite the impressive success of currently approved adjuvants for generating immunity to viral and bacterial infections, there remains a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines. However, the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens.
Subfields: Immunology
View Paper: https://www.semanticscholar.org/paper/4e44936ab79b8a0a2bd58b314f018876928989e6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “Interested readers can find more in-depth discussion in recent reviews (Coffman et al., 2010; Desmet and Ishii, 2012; Latz et al., 2013).”
- Modified mRNA vaccines protect against Zika virus infection (2017, neutral): “Although the adjuvant effect of stimulating innate immunity might be advantageous for protein vaccines, indiscriminate immune activation can inhibit mRNA translation, thus reducing antigen expression and immunogenicity of an mRNA vaccine (Claudio et al., 2013; Coffman et al., 2010).”
- Immunological mechanisms of vaccination (2011, neutral): “These include alum (an aluminum salt–based adjuvant), AS04 (a combination adjuvant composed of monophosphoryl lipid A (a TLR4 ligand) adsorbed to alum”
- Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. (2017, positive): “of PRR agonists are now under intense investigation for use as adjuvants that target specific innate immune cell recognition pathways.(62,63) For example, Monophosphoryl”